VisualSoft has managed to post a sequential growth of 4% in revenues and a commendable 18% growth in net profits for 3QFY02. Trouble for the company began in 4QFY01, when it gave a profit warning. It fell short of earnings guidance given previously due to a steep decline in its product sales. For the next two quarters things went from bad to worse and the company continued to post steep sequential fall in topline and bottomline. However, it seems that the worst is finally over for the company. Though on a YoY basis, the numbers look very disappointing, the revenues have declined by 40% and net profits have fallen by 73%, this is due to the fact the 3QFY01 was one the best for the company.
The most positive aspect of the result is that not only has the company managed to post a sequential growth in topline, it has also improved operating margins. VisualSoft has achieved this by exercising a tight control on costs. The expenses have actually declined sequentially.
(Rs m) | 2QFY02 | 3QFY02 | Change |
Sales | 234 | 244 | 4.6% |
Other Income | 16 | 16 | -1.4% |
Expenditure | 182 | 180 | -1.5% |
Operating Profit (EBDIT) | 51 | 65 | 26.2% |
Operating Profit Margin (%) | 22.0% | 26.6% | |
Interest | - | - | |
Depreciation | 19 | 22 | 15.0% |
Profit before Tax | 49 | 59 | 21.3% |
Tax | 2 | 4 | 90.5% |
Profit after Tax/(Loss) | 47 | 55 | 18.2% |
Net profit margin (%) | 20.0% | 22.6% | |
Diluted number of shares (m) | 19.7 | 19.7 | |
Diluted Earnings per share* | 9.5 | 11.2 | |
P/E (at current price) | 13.8 | ||
*(annualised) |
The company’s product sales, however, continue to be in trouble. The figures have shown a significant 39% decline sequentially. Consequently, the contribution to revenues from product has declined further. It is the revenues from services that have helped company post a sequential growth in revenues. The company added 6 new clients during the quarter taking the total number of clients to 47.
At the current market price of Rs 155, the stock is trading at a P/E multiple of 14x its 3QFY02 annualised earnings. Considering the uncertainty in growth the stock price is likely to remain range bound in the near future. One should wait for the company to outline a clear strategy for growth and show some consistent performance before considering the stock as an investment option.
Sorry! There are no related views on news for this company/sector.
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.
Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.
More
Equitymaster requests your view! Post a comment on "VisualSoft: Beginning of a recovery? ". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!